{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:59:47Z","timestamp":1793818787044,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>The effectiveness of immunosuppressive and corticosteroid treatments for Immunoglobulin A (IgA) nephropathy (IgAN) remains thoroughly evaluated. We undertook a meta-analysis to investigate the efficacy and safety of low-dose corticosteroids plus leflunomide for progressive IgA nephropathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible studies were obtained from PubMed, Embase, and Cochrane Library databases. We also searched the references of the included studies. Our protocol followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. Eligibility criteria were defined using a PICOS framework.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our study included three articles presenting 342 patient cases. Findings revealed that low-dose corticosteroids combined with the leflunomide group were effective in relieving urine protein excretion (UPE) [mean difference (MD) = -0.35, 95% confidence interval (CI): -0.41 to -0.30, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001] compared with the full-dose corticosteroids group. Regarding serum creatinine (SCr), estimated glomerular filtration rate (eGFR), complete remission rate, and overall response rate, there was no difference between the groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Regarding safety, low-dose corticosteroids combined with leflunomide significantly reduced the risk of serious adverse events [odds ratio (OR): 0.11, 95% CI: 0.01 to 0.91, <jats:italic>P<\/jats:italic>\u2009=\u20090.04]. Besides, no significant differences were observed between the two groups in the incidence of respiratory infection, abnormal liver function, diarrhea, herpes zoster, alopecia, pruritus, insomnia, pneumonia, diabetes, and urinary tract infection (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Low-dose corticosteroids combined with leflunomide are a safe and effective treatment for progressive IgA nephropathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The PROSPERO registration number is CRD42022361883.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-024-01438-3","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T08:01:46Z","timestamp":1710144106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Dongxu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"6","key":"1438_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1172\/JCI109998","volume":"66","author":"ME Conley","year":"1980","unstructured":"Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest. 1980;66(6):1432\u20136. https:\/\/doi.org\/10.1172\/JCI109998.","journal-title":"J Clin Invest"},{"issue":"4","key":"1438_CR2","first-page":"939","volume":"1","author":"J Berger","year":"1969","unstructured":"Berger J. IgA glomerular deposits in renal disease. Transpl Proc. 1969;1(4):939\u201344.","journal-title":"Transpl Proc"},{"issue":"25","key":"1438_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"J Robert","year":"2013","unstructured":"Robert J, Wyatt, Bruce A, Julian. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314. https:\/\/doi.org\/10.1056\/NEJMra1206793.","journal-title":"N Engl J Med"},{"issue":"2","key":"1438_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"FM Anita McGrogan, Casper","year":"2011","unstructured":"Anita McGrogan, Casper FM, Franssen, Corinne S, de Vries. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2011;26(2):414\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfq665.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"1438_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s0272-6386(97)90333-4","volume":"29","author":"A Koyama","year":"1997","unstructured":"Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal diseases. Am J Kidney Dis. 1997;29(4):526\u201332. https:\/\/doi.org\/10.1016\/s0272-6386(97)90333-4.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1438_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","volume":"24","author":"DA Giuseppe","year":"2004","unstructured":"Giuseppe DA. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179\u201396. https:\/\/doi.org\/10.1016\/j.semnephrol.2004.01.001.","journal-title":"Semin Nephrol"},{"issue":"1","key":"1438_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semnephrol.2007.10.001","volume":"28","author":"C Fran\u00e7ois","year":"2008","unstructured":"Fran\u00e7ois C, Berthoux H, Mohey. A\u00efda Afiani. Natural history of primary IgA nephropathy. Semin Nephrol. 2008;28(1):4\u20139. https:\/\/doi.org\/10.1016\/j.semnephrol.2007.10.001.","journal-title":"Semin Nephrol"},{"key":"1438_CR8","doi-asserted-by":"publisher","unstructured":"Chapter 10. Immunoglobulin A nephropathy. Kidney Int Suppl (2011). 2012;2(2):209\u2013217. https:\/\/doi.org\/10.1038\/kisup.2012.23.","DOI":"10.1038\/kisup.2012.23"},{"issue":"1","key":"1438_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53(1):26\u201332. https:\/\/doi.org\/10.1053\/j.ajkd.2008.07.029. Epub 2008 Oct 19.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1438_CR10","doi-asserted-by":"publisher","first-page":"CD003965","DOI":"10.1002\/14651858.CD003965.pub3","volume":"3","author":"C Patrizia Natale, Suetonia","year":"2020","unstructured":"Patrizia Natale, Suetonia C, Palmer M, Ruospo, et al. Cochrane Database Syst Rev. 2020;3(3):CD003965. https:\/\/doi.org\/10.1002\/14651858.CD003965.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl1","key":"1438_CR11","doi-asserted-by":"publisher","first-page":"i30","DOI":"10.1093\/ndt\/gfw342","volume":"32","author":"I Ali","year":"2017","unstructured":"Ali I, Al-Lawati, Heather N, Reich. Is there a role for immunosuppression in immunoglobulin A nephropathy? Nephrol Dial Transpl. 2017;32(suppl1):i30\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfw342.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"1438_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbrc.2018.01.107","volume":"496","author":"C Zhang","year":"2018","unstructured":"Zhang C, Chu M. Leflunomide: a promising drug with good antitumor potential. Biochem Biophys Res Commun. 2018;496(2):726\u201330.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.5414\/cnp71625","volume":"71","author":"X-Y Jiang","year":"2009","unstructured":"Jiang X-Y, Mo Y, Sun L-Z, et al. Efficacy of methylprednisolone, cyclophosphamide in pediatric IgA nephropathy assessed by renal biopsy. Clin Nephrol. 2009;71(6):625\u201331. https:\/\/doi.org\/10.5414\/cnp71625.","journal-title":"Clin Nephrol"},{"issue":"3","key":"1438_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"S Josef","year":"2014","unstructured":"Josef S, Smolen R, Landew\u00e9, Ferdinand C, Breedveld, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573. Epub 2013 Oct 25.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1438_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nep.12359","volume":"20","author":"D Genyang Cheng","year":"2015","unstructured":"Genyang Cheng D, Liu P, Margetts, et al. Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin a nephropathy. Nephrol (Carlton). 2015;20(2):77\u201384. https:\/\/doi.org\/10.1111\/nep.12359.","journal-title":"Nephrol (Carlton)"},{"issue":"2","key":"1438_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1440-1797.2006.00547.x","volume":"11","author":"C Tanqi Lou","year":"2006","unstructured":"Tanqi Lou C, Wang Z, Chen, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrol (Carlton). 2006;11(2):113\u20136. https:\/\/doi.org\/10.1111\/j.1440-1797.2006.00547.x.","journal-title":"Nephrol (Carlton)"},{"issue":"10","key":"1438_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005. Epub 2009 Jul 23.","journal-title":"J Clin Epidemiol"},{"key":"1438_CR18","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"T Miranda Cumpston","year":"2019","unstructured":"Miranda Cumpston T, Li MJ, Page, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1438_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"E Karem Slim","year":"2003","unstructured":"Karem Slim E, Nini D, Forestier, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"1438_CR20","unstructured":"Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.3.0. The Cochrane Collaboration. Available from: www.cochrane-handbook.org."},{"key":"1438_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin T Rials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin T Rials"},{"issue":"29","key":"1438_CR22","doi-asserted-by":"publisher","first-page":"48375","DOI":"10.18632\/oncotarget.16468","volume":"8","author":"Q Lulin Min","year":"2017","unstructured":"Lulin Min Q, Wang L, Cao, et al. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. Oncotarget. 2017;8(29):48375\u201384. https:\/\/doi.org\/10.18632\/oncotarget.16468.","journal-title":"Oncotarget"},{"issue":"1","key":"1438_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/0886022X.2021.1963775","volume":"43","author":"Z Ni","year":"2021","unstructured":"Ni Z, Zhang Z. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial. Ren Fail. 2021;43(1):1214\u201321. https:\/\/doi.org\/10.1080\/0886022X.2021.1963775.","journal-title":"Ren Fail"},{"issue":"1","key":"1438_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12882-021-02555-z","volume":"22","author":"Y Li","year":"2021","unstructured":"Li Y, Xiong Y, Huang T, et al. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy. BMC Nephrol. 2021;22(1):364. https:\/\/doi.org\/10.1186\/s12882-021-02555-z.","journal-title":"BMC Nephrol"},{"key":"1438_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.12659\/AOT.907167","volume":"23","author":"DBC Cabral","year":"2018","unstructured":"Cabral DBC, de Sandes-Freitas TV, Medina-Pestana JO, et al. Clinical features, treatment and prognostic factors of post-transplant immunoglobulin A nephropathy. Ann Transplant. 2018;23:166\u201375. https:\/\/doi.org\/10.12659\/AOT.907167.","journal-title":"Ann Transplant."},{"issue":"1","key":"1438_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1681\/ASN.2017060713","volume":"29","author":"C Thomas Rauen","year":"2018","unstructured":"Thomas Rauen C, Fitzner F, Eitner, et al. Effects of two immunosuppressive treatment protocols for IgA Nephropathy. J Am Soc Nephrol. 2018;29(1):317\u201325. https:\/\/doi.org\/10.1681\/ASN.2017060713. Epub 2017 Oct 17.","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"1438_CR27","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"F Thomas Rauen","year":"2015","unstructured":"Thomas Rauen F, Eitner C, Fitzner, et al. Intensive supportive care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373(23):2225\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1415463.","journal-title":"N Engl J Med"},{"issue":"1","key":"1438_CR28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/0886022X.2022.2085576","volume":"44","author":"G Lv","year":"2022","unstructured":"Lv G. Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials. Ren Fail. 2022;44(1):1011\u201325. https:\/\/doi.org\/10.1080\/0886022X.2022.2085576.","journal-title":"Ren Fail"},{"issue":"2","key":"1438_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11255-012-0313-y","volume":"45","author":"C Linshen Xie","year":"2013","unstructured":"Linshen Xie C, Tan J. Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating cosmc expression in IgA nephropathy. Int Urol Nephrol. 2013;45(2):571\u20139. https:\/\/doi.org\/10.1007\/s11255-012-0313-y. Epub 2012 Nov 8.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"1438_CR30","first-page":"375","volume":"123","author":"Yi-zhi Chen","year":"2010","unstructured":"Chen Yi-zhi, Zhao Xue-zhi, Wu J, et al. Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy. Chin Med J (Engl). 2010;123(3):375\u20138.","journal-title":"Chin Med J (Engl)"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01438-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T08:02:15Z","timestamp":1710144135000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01438-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01438-3","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"28 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}